Trending Topic

3D rendered Medical Illustration of Male Anatomy - Rectal Cancer.
14 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Gabriel Valagni, Nkafu Bechem Ndemazie, Tiago Biachi de Castria

Trifluridine/tipiracil (FTD/TPI) is a novel oral formulation of two drugs with promising results in the treatment of metastatic colorectal cancer (mCRC).1 Trifluridine is a thymidine-based nucleoside analogue that, after intracellular phosphorylation, gets incorporated into DNA, causing DNA dysfunction.2 It was first identified by Callahan et al. in 1996 as an active impurity in the herbicide trifluralin, which […]

CME Accredited Learning

Our accredited content is designed to impact patient health outcomes, by ensuring that it provides you with a learning experience that will positively impact your clinical practice, based on adult learning preferences and intuitive instructional design. All activities are developed in collaboration with leading faculty and education partners.

touchONCOLOGY

Speciality Filter

Select Specialty or Clinical Area

Clear All
Update Filters
Close Popup
39 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchMDT
Dr Lizza Hendriks, Dr Jacob Sands, Prof. Suresh Senan

A multidisciplinary team discusses the role of immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC).

55 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchMDT
Dr Xiuning Le, Dr Christine Argento, Dr Sandra Cuellar, Ms Stephanie McDonald, Prof. Albrecht Stenzinger

A multidisciplinary team of specialists discuss the use of targeted therapies for NSCLC with MET alterations.

64 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchCLINICAL PERSPECTIVES
Dr Helena Yu, Dr Antonio Passaro, Dr Aaron Lisberg, Dr Sara Pilotto

Experts provide insights on tailoring treatment in patients with EGFR-mutant and wildtype NSCLC.

15 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked

Watch an expert in lung cancer discuss the treatment options for patients with early-stage EGFR-mutant NSCLC

55 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchCONGRESS
Prof. María-Victoria Mateos, Dr Rakesh Popat, Prof. Evangelos Terpos

Three experts discuss data presented at COMy and EHA 2024 on BCMA-targeting agents in multiple myeloma.

15 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked

Watch Prof. Barbara Burtness provide an update on the evolving role of ICIs in the management of RM-NPC.

41 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchPANEL DISCUSSION
Dr Razelle Kurzrock, Dr Lyudmila Bazhenova, Dr Ignacio Wistuba

Two oncologists and a pathologist discuss the implications of HER2 targeting in solid tumours, with a focus on NSCLC.

51 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchCONGRESS
Dr Vickie McDonald, Prof. Waleed Ghanima, Prof. James B Bussel

Three experts discuss data presented at EHA and ISTH 2024 on the impact and management of ITP.

18 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked

Watch an expert in RCC discuss multidisciplinary team care for patients with early through advanced disease.

Society & Congress Partners

touchONCOLOGY is proud to partner with leading medical societies and congresses from around the world to bring you news and insight from virtual and live events

View All
39 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchPANEL DISCUSSION
Dr Matthew Lunning, Professor Charalambos Andreadis, Dr Tara Graff

Haematology experts discuss the latest on novel therapies and treatment selection and sequencing in R/R FL

15 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked

Watch Dr Dana Chase discuss the role of HER2 as a pan-tumour biomarker and the implications for treatment.

39 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchIN CONVERSATION
Ms Nikolina Dodlek, Prof. Sherko Kümmel

Watch an oncology nurse and a medical oncologist discuss the use of HER2-directed ADCs in breast cancer.

37 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchIN CONVERSATION
Prof. Enriqueta Felip, Prof. Keith Kerr

An oncologist and a pathologist discuss HER2 testing and treatments for HER2-altered NSCLC.

52 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchPANEL DISCUSSION
Prof. Dr Vito Sabato, Dr Sigurd Broesby-Olsen, Prof. Prithviraj Bose

Multidisciplinary experts discuss the diagnosis and management of patients with systemic mastocytosis.

33 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked

Prof. Wakelee discusses the latest evidence on immunotherapy for early-stage, resectable NSCLC.

32 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked

Prof. Powles considers the latest developments in the treatment of advanced urothelial carcinoma.

38 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked

Hear expert insights on the role of immunotherapy in treating advanced/recurrent endometrial cancer.

42 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchIN CONVERSATION
Dr Juan Manuel O’Connor, Prof. Dr Francesco Sclafani

Watch GI oncologists discuss navigating the biomarker landscape to implement personalized treatment in CRC.

Load More...

All touchIME CME activities are accredited. Learners can claim ACCME, ANCC, ACPE or EBAC credits upon completion of the activities. This content is for healthcare professionals only.

Close Popup